Skip to main content
Clinical Trials/NCT05643001
NCT05643001
Completed
Not Applicable

Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke

Massachusetts General Hospital1 site in 1 country340 target enrollmentMarch 15, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemorrhagic Stroke
Sponsor
Massachusetts General Hospital
Enrollment
340
Locations
1
Primary Endpoint
Proportion of patients with LDL measurements
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

The overall goal of this study is to increase health care provider awareness for common risk factors and comorbidities in patients with hemorrhagic stroke that are related to impaired brain health, to ultimately improve patients management and associated outcomes. The specific objective is to test the performance and effectiveness of a custom electronic health record (EHR)-based notification module at time of index hospitalization and at follow-up for hemorrhagic stroke survivors, before disparities in access to outpatient care may limit opportunities to intervene.

The investigators hypothesize that notification of health care providers through the EHR will increase measurements of low-density lipoprotein (LDL) and glycated hemoglogbin A1c (HbA1c) and increase evaluation and management rates for obstructive sleep apnea and hearing impairment.

Registry
clinicaltrials.gov
Start Date
March 15, 2023
End Date
March 28, 2025
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher D. Anderson, MD, MMSc

Division Chief of Stroke and Cerebrovascular Disease

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 years or older
  • Presenting with a primary diagnosis of hemorrhagic stroke admitted to Massachusetts General Hospital inpatient stroke service

Exclusion Criteria

  • Patients not meeting above inclusion criteria
  • Patients presenting with subdural or epidural hematoma

Outcomes

Primary Outcomes

Proportion of patients with LDL measurements

Time Frame: 12 months

Proportion of patients with any LDL measurements in the 12-months period surrounding acute hemorrhagic stroke (6-months before and 6-months follow-up following discharge). LDL measurements will be ascertained based on electronic health record documentation.

Proportion of patients with HbA1c measurements

Time Frame: 12 months

Proportion of patients with any HbA1c measurements in the 12-months period surrounding acute hemorrhagic stroke (6-months before and 6-months follow-up following discharge). HbA1c measurements will be ascertained based on electronic health record documentation.

Secondary Outcomes

  • Proportion of patients with management of obstructive sleep apnea(6-months)
  • Proportion of patients with management of hearing impairment(6-months)
  • Proportion of patients with intensification of lipid-lowering therapy(6-months)
  • Proportion of patients with intensification of antidiabetic therapy(6-months)

Study Sites (1)

Loading locations...

Similar Trials